 |
|
|
 |
|
Rationale:
- Close contacts of persons with HAV are at risk for infection.
- Hepatitis A vaccine or immunoglobulin administered within 2 weeks of exposure can prevent or attenuate HAV infection.
- It is generally accepted that poor sanitation contributes to HAV transmission.
|
|
Evidence:
- Hepatitis A vaccine or immunoglobulin administered intramuscularly within 2 weeks of exposure is effective in preventing symptomatic
infection among exposed persons (24; 33; 69; 70; 71; 72).
|
|
Comments:
|
| FAQs |
|
|
|
Brian J. McMahon, MD, MACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Catherine M. Dentinger, FNP, MS has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
Hepatitis A
> Patient Education
